

# **HHS Public Access**

Biochem Biophys Res Commun. Author manuscript; available in PMC 2020 July 05.

Published in final edited form as:

Author manuscript

Biochem Biophys Res Commun. 2019 July 05; 514(4): 1204–1209. doi:10.1016/j.bbrc.2019.05.098.

# Oxidative stress induces senescence in breast cancer stem cells

Guangxian Zhong<sup>1,2</sup>, Shenghui Qin<sup>1</sup>, Danyelle Townsend<sup>3</sup>, Bradley A. Schulte<sup>1</sup>, Kenneth D. Tew<sup>4,5</sup>, and Gavin Y. Wang<sup>1,5,\*</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA

<sup>2</sup>Department of Orthopaedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350000, P.R. China

<sup>3</sup>Department of Drug Discovery and Biomedical Sciences

<sup>4</sup>Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC 29425, USA

<sup>5</sup>Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA

# Abstract

Cancer stem cells (CSCs) have been shown to be resistant to current anticancer therapies and the induction of oxidative stress is an important mechanism of action for many anticancer agents. However, it is still largely unknown how CSCs respond to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced oxidative stress. Here, we show that the levels of reactive oxygen species (ROS) are markedly lower in breast CSCs (BCSCs) than that in non-cancer stem cells (NCSCs). A transient exposure of breast cancer cells to sublethal doses of H2O2 resulted in a dose-dependent increase of the epithelium-specific antigen (ESA)<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup>subpopulations, a known phenotype for BCSCs. Although BCSCs survived sublethal doses of  $H_2O_2$  treatment, they lost the ability to form tumor spheres and failed to generate colonies as demonstrated by mammosphere-formation and clonogenic assays, respectively. Mechanistic studies revealed that H<sub>2</sub>O<sub>2</sub> treatment led to a marked increase of senescence-associated  $\beta$ -galactosidase activity but only minimal apoptotic cell death in BCSCs. Furthermore,  $H_2O_2$  triggers p53 activation and promotes p21 expression, indicating a role for the p53/p21 signaling pathway in oxidative stress-induced senescence in BCSCs. Taken together, these results demonstrate that the maintenance of a lower level of ROS is critical for CSCs to avoid oxidative stress and H<sub>2</sub>O<sub>2</sub>-induced BCSC loss of function is likely attributable to oxidative stress-triggered senescence induction, suggesting that ROS-generating drugs may have the therapeutic potential to eradicate drug-resistant CSCs via induction of premature senescence.

Conflicts of interest

The authors declare no conflict of interest.

<sup>&</sup>lt;sup>\*</sup>Correspondence to: Gavin Y. Wang, MD, PhD, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 171 Ashley Avenue, MSC908, Charleston, SC 29425 Tel: 1-843-792-9983; Fax: 1-843-792-0368, wangy@musc.edu. **Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Oxidative stress; Breast cancer; Cancer stem cells; Senescence; Hydrogen peroxide

# 1. Introduction

Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are a small subpopulation of cells within a heterogeneous tumor that have the unique ability to drive tumor initiation, progression and metastasis [1, 2]. Emerging evidence has suggested that CSCs are resistant to current anticancer therapies, as demonstrated by the fact that they are enriched in residual tumors following chemotherapy and/or radiation [3–6]. Induction of oxidative stress has been shown to be a crucial mechanism of action for many anticancer agents including radiation [7–9]. However, it is largely unknown how drug-resistant CSCs respond to oxidative stress. The goal of this study was to delineate the response of breast cancer stem cells (BCSCs) to  $H_2O_2$ -induced oxidative stress.

Cellular senescence is a state of irreversible cell cycle arrest that can be triggered by various cell-intrinsic and extrinsic stimuli, including DNA damage, oxidative stress, and exposure to chemotherapeutic agents and ionizing radiation [10]. Although the induction of apoptotic cell death was thought to be a desirable outcome for cancer therapy, we and others have shown that senescence induction in tumor cells is a common therapeutic response to many anticancer modalities including CDK4/6 small molecule inhibitor-based targeted therapeutics and radiation treatment [10–15]. In this study, we demonstrate that  $H_2O_2$ -mediated oxidative stress induces premature senescence, but not apoptosis in BCSCs. We also show that  $H_2O_2$ -induced BCSC senescence is associated with p53 activation as well as increased p53 and p21 expression, implying a role of the p53/p21 signaling pathway in oxidative stress-induced senescence and that certain ROS-generating drugs may have the therapeutic potential to functionally disable drug-resistant CSCs via induction of premature senescence.

# 2. Materials and Methods

#### 2.1. Cell lines, reagents and antibodies

The SUM series of human breast cancer cell lines including SUM159 and SUM149 cells were developed by Dr. Stephen Ethier at the Medical University of South Carolina (MUSC). We received these cell lines directly from Dr. Ethier's laboratory at MUSC and the cells were maintained as previously described [16]. The MCF-7 human breast cancer cell line was purchased from American Type Culture Collection (ATCC) and the cells were cultured in DMEM medium containing 10% FBS, 2 mM L-glutamine and 100 microgram/mL of penicillin-streptomycin (Invitrogen). Dulbecco's modified Eagle's medium (DMEM), DMEM/F12 medium, recombinant human basic fibroblast growth factor (bFGF) and B27 supplement were obtained from Invitrogen (Carlsbad, CA). Recombinant human epithelial growth factor (rhEGF) was purchased from R&D systems. Heparin and hydrocortisone were purchased from Stem Cell Biotechnologies (Vancouver, BC). Rabbit anti-human

phosphorylated p53 (p-p53), p53 and p21 antibodies were purchased from Cell Signaling

(Danvers, MA). Mouse anti-human tubulin monoclonal antibodies were obtained from Santa Cruz Biotechnology. 2'-7'-Dichlorodihydrofluorescein diacetate (DCF-DA) and ImaGene GreenTM C<sub>12</sub>FDG lacZ gene expression kit were purchased from Invitrogen. The FITC Annexin V Apoptosis Detection kit was obtained from BD Biosciences.

#### 2.2. BCSC flow cytometry analysis and intracellular ROS detection

The ESA<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup>subpopulations were identified as the CSCs in breast cancer [17]. Flow cytometry was employed to quantify ESA<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup> BCSCs as previously described [16, 17]. Briefly, MCF-7 or SUM159 cells were resuspended in 2% FBS/DPBS and incubated with PE-conjugated mouse anti-human ESA (ESA), APC-conjugated mouse anti-human CD44 and BV421-conjugated mouse anti-human CD24 (both from BD Biosciences) for 20 min on ice. After washing with 2% FBS/DPBS, the frequency of ESA<sup>+</sup>/ CD44<sup>+</sup>/CD24<sup>-</sup>BCSCs was analyzed using a BD LSRFortessa<sup>TM</sup> X-20 Flow Cytometer (BD Biosciences).

DCF-DA, a well-characterized ROS probe [18], was utilized to detect and measure ROS in different subpopulations of breast cancer cells using flow cytometry as previously reported [19]. Briefly, after labeling with the CSC surface markers (ESA, CD24 and CD44) as described above, the cells were incubated with DCF-DA (5  $\mu$ M) at 37°C for 30 min. ROS levels in BCSC and NCSC subpopulations were measured using a BD LSRFortessaTM X-20 Flow Cytometer (BD Biosciences). Data were processed and analyzed using FlowJo software.

# 2.3. Mammosphere formation assay

Mammosphere formation assay (MFA) was employed to determine the sphere-forming activity of CSCs as previously described [16, 20]. Briefly, single-cell suspensions were prepared at 24 h after H<sub>2</sub>O<sub>2</sub> exposure and cultured in 24-well ultra-low attachment plates (Corning) using serum-free DMEM/F-12 medium supplemented with 20 ng/mL basic FGF, 20 ng/mL EGF, 4  $\mu$ g/mL insulin, 4  $\mu$ g/mL heparin, 0.5  $\mu$ g/mL hydrocortisone, 0.4% BSA and B27 nutrient supplement (Invitrogen). Culture medium was replaced in half every other day with 50% fresh medium. Mammospheres were counted and photographed after 7 days of culture.

# 2.4. Clonogenic assay

MCF-7 or SUM159 cells were transiently exposed to a range of sublethal doses (100 to 500 uM) of  $H_2O_2$  for 2 h. Then, the cells were washed with PBS to remove  $H_2O_2$  and re-fed with complete medium. At 24 h after exposure, cells were collected and cultured in 60 mm dishes at low density for 12 - 14 days to allow the formation of cell colonies. The colonies were fixed and stained with 0.5% crystal violet (Sigma) in methanol for 30 min. The number of colonies (50 cells) was scored and photographed as described previously [21].

#### 2.5. Apoptosis analysis

After staining with CSC surface markers, apoptotic cells were labeled with FITC-conjugated Annexin V and 7-AAD using a FITC Annexin V Apoptosis Detection kit (BD Biosciences) and analyzed using a BD LSRFortessa<sup>TM</sup> X-20 Flow Cytometer as previously reported [22].

#### 2.6. Senescence assays

In situ SA- $\beta$ -gal assays were performed to determine senescent cells in bulk tumor cells using a senescence  $\beta$ -galactosidase staining kit (Cell Signaling) as we have reported previously [11, 21]. SA- $\beta$ -gal activity in BCSCs was measured by flow cytometry using an ImaGene GreenTM C<sub>12</sub>FDG lacZ gene expression kit (Invitrogen) according to the manufacturer's instruction and a published protocol [23] with some minor modifications. Briefly, after staining with BCSC surface markers, the cells were incubated with 25  $\mu$ M chloroquine at 37°C for 30 to inhibit endogenous  $\beta$ -galactosidase activity. Then, the cells were incubated with 20  $\mu$ M C<sub>12</sub>FDG at 37°C for 20 minutes. SA- $\beta$ -gal positive senescent cells in the ESA<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup> subpopulations were measured using a BD LSRFortessa<sup>TM</sup> X-20 Flow Cytometer (BD Biosciences). Data were processed and analyzed using FlowJo software.

#### 2.7. Western blot analysis

Western blot analyses were performed as previously described [16]. Briefly, protein samples were extracted using cell lysis buffer (Cell Signaling) supplemented with a cocktail of proteinase inhibitors (Sigma). The protein concentrations were quantified using a Bio-Rad Dc protein assay kit (Bio-Rad Laboratories, Hercules, CA). Fifty microgram protein samples were resolved on 4 - 20% Mini-Protean TGX gels (Bio-Rad) and transferred onto 0.2  $\mu$ M PVDF membrane (Millipore). Blots were blocked with 5% non-fat milk for one hour at room temperature and then incubated with primary antibodies at 4°C overnight. After extensive washing with TBS-T, blots were incubated with appropriate HRP-conjugated secondary antibody for 1.5 h at room temperature. Protein bands were detected using an ECL Plus Western Blotting Detection System (GE Healthcare Life Science).

#### 2.8. Statistical analysis

Comparisons between groups were carried out using Student's *t*-test. Differences were considered statistically significant at p < 0.05. The error bars indicate SEM. All analyses were carried out with the GraphPad Prism program (GraphPad Software, Inc. San Diego, CA).

# 3. Results

#### 3.1. BCSCs display lower levels of ROS compared with NCSCs

Our previous studies have demonstrated that hematopoietic stem cells (HSCs) are susceptible to ionizing radiation-induced oxidative stress [19, 24]. It also has been shown that HSCs with lower levels of ROS exhibit greater self-renewal potential and hematopoiesis-reconstituting capacity than cells with high levels of ROS [25]. Moreover, there is evidence that oxidative stress is harmful to HSCs, impairing HSC self-renewal

potential and its long-term blood cellrepopulating capacity [26–28]. However, it remains to be determined how CSCs respond to oxidative stress. To gain insight into the redox status in BCSCs, we utilized a well-characterized ROS probe, DCF-DA, along with flow cytometry to quantify ROS levels in ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> BCSCs (Fig. 1A). Our data showed that ROS levels in NCSCs are approximately 5-fold higher than that in BCSCs from SUM159 cells (Fig. 1B & C). Similarly, the levels of ROS in BCSCs are markedly lower than that in

#### 3.2. H<sub>2</sub>O<sub>2</sub> treatment has no significant effect on apoptotic cell death in BCSCs

NCSCs from MCF7 cells (Fig. 1D).

 $H_2O_2$  has been widely used to induce oxidative stress in various types of cells [29, 30]. To examine how BCSCs respond to oxidative stress, we investigated the effects of  $H_2O_2$  on BCSC survival and apoptotic cell death. Surprisingly, we found that sublethal doses of  $H_2O_2$ treatment increases the frequency of ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> subpopulations in a dosedependent manner (Fig. 2A & B). Furthermore, our subsequent studies revealed that a transient treatment with  $H_2O_2$  failed to induce apoptotic cell death in BCSCs (Fig. 2C & D). In contrast, camptothecin (CPT) treatment led to a substantial increase of apoptosis in ESA<sup>+</sup>/ CD24<sup>-</sup>/CD44<sup>+</sup> BCSCs (Fig. 2C & D). These results suggest that sublethal dose  $H_2O_2$ mediated oxidative stress has no significant effect on apoptosis induction in BCSCs.

#### 3.3. Oxidative stress impairs the mammosphere-forming potential of BCSCs

The mammosphere formation assay (MFA) is a very useful technique to measure the sphereforming ability of CSCs and the sphere-initiating cells (SICs) have been considered as the surrogate of CSCs in culture [16, 20]. To examine the effects of  $H_2O_2$ -induced oxidative stress on CSC function, we took advantage of the MFA to measure the sphere-forming ability of MCF-7 and SUM159 cells after a transient exposure to  $H_2O_2$  (Fig. 3A). The results showed that  $H_2O_2$  treatment causes a dose-dependent decrease in the number of mammospheres generated from both MCF-7 and SUM159 cells (Fig. 3B & C).

The clonogenic assay (also known as colony formation assay) is a well-characterized *in vitro* experiment that measures the reproductive capacity of a single cell to generate a colony in longterm culture, thus defining a cell's ability to replicate and form a tumor [31]. Using clonogenic assays, we demonstrated that  $H_2O_2$  exposure suppresses the colony-forming capacity of both MCF-7 and SUM159 cells in a dose-dependent fashion (Fig. 3D–F). Together, these results suggest that although BCSCs can survive sublethal doses of  $H_2O_2$  treatment (Fig. 2A–D), they lose the ability to produce mammospheres and to generate colonies in culture (Fig. 3A–F).

#### 3.4. Oxidative stress induces premature senescence in BCSCs

Induction of senescence is an important mechanism of tumor prevention by limiting the reproductive capacity of cells. We and others have shown that  $H_2O_2$ -mediated oxidative stress can readily induce premature senescence in a variety of cells [29, 32]. However, it remains to be determined if  $H_2O_2$ -mediated oxidative stress causes premature senescence in BCSCs. To gain insights into the role of senescence induction in  $H_2O_2$ -induced loss of function in BCSCs, we examined if  $H_2O_2$  treatment induces senescence in breast cancer cells, and more importantly in BCSCs. SA- $\beta$ -gal analyses revealed that treatment with  $H_2O_2$ 

causes a dose-dependent increase of senescent cells in both MCF-7 and SUM159 cells (Fig. 4A–C). Our subsequent flow cytometry assays further indicated that SA- $\beta$ -gal positive cells were markedly increased in the ESA/CD24/CD44 subpopulations in response to H<sub>2</sub>O<sub>2</sub> treatment (Fig. 4D & E). These results demonstrate for the first time that H<sub>2</sub>O<sub>2</sub>-mediated oxidative stress induces premature senescence in BCSCs.

Our previous studies have shown that activation of the p53/p21 signaling pathway plays a pivotal role in mediating ionizing radiation-induced senescence in lung cancer cells [11]. To elucidate the mechanisms by which oxidative stress induces senescence in BCSCs, we investigated the effects of  $H_2O_2$  on p53/p21 signaling. Western blot analyses revealed that  $H_2O_2$  treatment led to a dose-dependent increase in the expression levels of phosphorylated p53 (p-p53), suggesting that  $H_2O_2$ -mediated oxidative stress may activate the p53 signaling pathway (Fig. 4F). In agreement with this suggestion, we found that both p53 and p21 expression levels were markedly increased by  $H_2O_2$  treatment (Fig. 4F). Together, these results suggest that  $H_2O_2$  may induce senescence in BCSCs at least in part by activation of the p53/p21 signaling pathway.

# 4. Discussion

Oxygen metabolism in mitochondria is a crucial process for ATP production to provide energy for cell survival and functional activity needs, but it also leads to the generation of ROS, because of electron leak during oxidative phosphorylation and reduction of O2 molecules [33]. Mitochondrial ROS include superoxide anion, hydroxyl radical, H<sub>2</sub>O<sub>2</sub>, and singlet oxygen [33]. If the accumulation of ROS exceeds the scavenging capacity of the antioxidant system, it may disturb the redox balance, resulting in oxidative stress. We and others have shown that H<sub>2</sub>O<sub>2</sub>-mediated oxidative stress could induce premature senescence in various types of cells [29, 32]. However, it was largely unknown how BCSCs respond to H<sub>2</sub>O<sub>2</sub>-mediated oxidative stress until our present study. Our flow cytometry data revealed that ROS levels are markedly lower in BCSCs than that in NCSCs. These results suggest that it may be critical for CSCs to keep ROS at a low level to avoid oxidative stress-associated toxicity. In agreement with this idea, it has been shown that increasing ROS production by L-S,R-buthionine sulfoximine (BSO) treatment could sensitize CSCs to radiation [34]. Furthermore, our studies have demonstrated that transient exposure to sublethal doses of  $H_2O_2$  is sufficient to cause marked deficiency in the mammosphere-forming capacity of BCSCs. Mechanistically, we found that H<sub>2</sub>O<sub>2</sub> treatment-induced BCSC loss of function is attributable to the induction of premature senescence.

In addition, our studies have revealed for the first time that  $H_2O_2$ -mediated oxidative stress increases the number of BCSCs. In agreement with our observations, previous studies showed that chemotherapy and/or radiation led to the enrichment of the CSCs in residual tumors following anticancer treatments [3–6]. The increase of the ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> subpopulations by sublethal doses of  $H_2O_2$  treatment suggests that BCSCs are likely more resistant to  $H_2O_2$  treatment compared to NCSCs. Another possible explanation is that  $H_2O_2$ induced oxidative stress may simply reduce CD24 expression, leading to an "artificial" increase in the number of ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> cells. Nevertheless, further studies are

A growing body of evidence has suggested that CSCs play a critical role in drug resistance, metastatic progression and tumor relapse, leading to treatment failure [1, 2, 4, 35]. It has been shown that CSCs have increased DNA damage repair capacity than NCSCs [35, 36]. Oxidative stress can cause DNA damage, resulting in senescence induction. The observation that  $H_2O_2$ -treated BCSCs lost the ability to produce mammospheres and exhibited a significant increase in SA- $\beta$ -gal staining suggests that these cells are vulnerable to oxidative stress-mediated DNA damage and senescence induction. In agreement with this idea, our studies revealed that  $H_2O_2$ -induced BCSC loss of function and senescence phenotype is associated with p53 activation and increased p21 expression. Given that activation of the p53/p21 signaling pathway is a well-known DNA damage response process, these results suggest that oxidative stress-triggered DNA damage response is likely involved in  $H_2O_2$ -induced premature senescence and loss of function in BCSCs.

In conclusion, this study provides a novel insight into BCSC's response to  $H_2O_2$ -mediated oxidative stress. Even a transient exposure to sublethal doses of  $H_2O_2$  can induce premature senescence in BCSCs, resulting in the loss of function for these cells to generate tumor spheres in culture. These results suggest that selective ROS-generating agents may have the therapeutic potential for targeting drug-resistant and metastatic CSCs through promoting oxidative stress-induced CSC premature senescence.

# Acknowledgments

The authors thank Dr. Stephen Ethier for providing the SUM series of human breast cancer cell lines. This work was supported in part by NIH grant numbers P20GM103542 and UL1TR001450.

# References

- 1. Adorno-Cruz V, Kibria G, Liu X, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance, Cancer Res 75 (2015) 924–9. [PubMed: 25604264]
- 2. Oskarsson T, Batlle E, Massagué J, Metastatic stem cells: sources, niches, and vital pathways, Cell Stem Cell, 14 (2014) 306–21. [PubMed: 24607405]
- Freitas DP, Teixeira CA, Santos-Silva F, et al. Therapy-induced enrichment of putative lung cancer stem-like cells, Int. J. Cancer, 134 (2014) 1270–8. [PubMed: 24105655]
- Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance, Nature, 517 (2015) 209–13. [PubMed: 25470039]
- Lu H, Tran L, Park Y, et al. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment, Cancer Res 78 (2018) 4191–4202. [PubMed: 29880481]
- Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc. Natl. Acad. Sci. U S A, 106 (2009) 13820– 5. [PubMed: 19666588]
- Allen BG, Bhatia SK, Buatti JM, et al. Ketogenic diets enhance oxidative stress and radio-chemotherapy responses in lung cancerxenografts, Clin. Cancer Res 19 (2013) 3905–13. [PubMed: 23743570]
- Hou D, Liu Z, Xu X, et al. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer, Redox Biol 17 (2018) 99–111. [PubMed: 29684820]

- 9. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov 8 (2009) 579–91. [PubMed: 19478820]
- Qin S, Schulte BA, Wang GY. Role of senescence induction in cancer treatment. World J. Clin. Oncol 9 (2018) 180–187. [PubMed: 30622926]
- Luo H, Yount C, Lang H, et al. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence, Lung Cancer, 81 (2013) 167–73. [PubMed: 23683497]
- Luo H, Yang A, Schulte BA, Wargovich MJ, Wang GY. Resveratrol Induces Premature Senescence in Lung Cancer Cells via ROS-Mediated DNA Damage, PLoS One, 8 (2013) e60065. [PubMed: 23533664]
- te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP, DNA damage is able to induce senescence in tumor cells in vitro and in vivo, Cancer Res 62 (2002) 1876–83. [PubMed: 11912168]
- Acevedo M, Vernier M, Mignacca L, et al. A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence, Cancer Res 76 (2016) 3252–64. [PubMed: 27206849]
- Klein ME, Dickson MA, Antonescu C, et al. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence, Oncogene, 37 (2018) 5066–5078. [PubMed: 29789718]
- Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, Wang GY, MYC Inhibition depletes cancer stemlike cells in triple-negative breast cancer, Cancer Res 77 (2017) 6641–50. [PubMed: 28951456]
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. U S A, 100 (2003) 3983–8. [PubMed: 12629218]
- Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry, Methods Mol. Biol 594 (2010) 57–72. [PubMed: 20072909]
- Wang Y, Liu L, Pazhanisamy S, Meng A, Zhou D, Total body irradiation selectively induces persistent oxidative stress in murine hematopoietic stem cells, Free Radic. Biol. and Med 48 (2010) 348–56. [PubMed: 19925862]
- Kreso A, van Galen P, Pedley NM, et al. Self-renewal as a therapeutic target in human colorectal cancer, Nat. Med 20 (2014) 29–36. [PubMed: 24292392]
- He X, Yang A, McDonald DG, Riemer EC, Vanek KN, Schulte BA and Wang GY, MiR-34a modulates ionizing radiation-induced senescence in lung cancer cells, Oncotarget, 8 (2017) 69797–807. [PubMed: 29050242]
- 22. Xiao X, Luo H, Vanek KN, LaRue AC, Schulte BA, Wang GY, Catalase Inhibits Ionizing Radiation-Induced Apoptosis in Hematopoietic Stem and Progenitor Cells. Stem Cells Dev 24 (2015) 1342–51. [PubMed: 25603016]
- Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescenceassociated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo, Nat. Protoc 4 (2009) 1798–1806. [PubMed: 20010931]
- Li H, Wang Y, Pazhanisamy SK, et al. Mn(III) meso-tetrakis-(N-ethylpyridinium-2-yl) porphyrin mitigates total body irradiation-induced long-term bone marrow suppression, Free Radic. Biol. Med 51 (2011) 30–37. [PubMed: 21565268]
- 25. Jang YY, Sharkis SJ, A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche, Blood, 110 (2007) 3056–63. [PubMed: 17595331]
- 26. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells, Nat Med 12 (2006) 446–51. [PubMed: 16565722]
- Ito K, Hirao A, Arai F, Matsuoka S, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells, Nature, 431 (2004) 997–1002. [PubMed: 15496926]
- Yahata T, Takanashi T, Muguruma Y, et al. Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells, Blood, 118 (2011) 2941–50. [PubMed: 21734240]

- Burova E, Borodkina A, Shatrova A, Nikolsky N. Sublethal oxidative stress induces the premature senescence of human mesenchymal stem cells derived from endometrium, Oxid. Med. Cell Longev 2013 (2013) 474931. [PubMed: 24062878]
- Baker JR, Vuppusetty C, Colley T, et al. Oxidative stress dependent microRNA-34a activation via PI3Ka reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells, Sci Rep 6 (2006) 35871.
- Franken NA, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nat Protoc 1 (2006) 2315–9. [PubMed: 17406473]
- Wang Y, Meng A, Zhou D, Inhibition of phosphatidylinostol 3-kinase uncouples H2O2-induced senescent phenotype and cell cycle arrest in normal human diploid fibroblasts, Exp. Cell Res 298 (2004) 188–96. [PubMed: 15242773]
- Moloney JN, Cotter TG, ROS signaling in the biology of cancer, Semin. Cell Dev. Biol 80 (2018) 50–64. [PubMed: 28587975]
- 34. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells, Nature, 458 (2009) 780–3. [PubMed: 19194462]
- Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int. J. Radiat. Biol 90 (2014) 615–21. [PubMed: 24527669]
- 36. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, 444 (2006) 756–60. [PubMed: 17051156]

# Highlights

• ROS levels are markedly lower in BCSCs than that in NCSCs

- Exposure to sublethal doses of H<sub>2</sub>O<sub>2</sub> increases the number of BCSCs
- Oxidative stress causes the loss of function in BCSCs via induction of senescence
- H<sub>2</sub>O<sub>2</sub>-induced BCSC senescence is associated with activation of the p53/p21 pathway



#### Fig. 1. ROS levels are markedly lower in BCSCs than that in NCSCs.

DCF-DA staining and flow cytometry assays were performed to measure ROS levels in BCSCs and NCSCs. (A) Representative flow cytometry graphs are presented, showing the gating strategy for detecting ROS levels in BCSCs and NCSCs. (B) ROS levels are presented as mean fluorescence intensity (MFI) of DCF-DA staining. Overlaid flow cytometry graphs indicate that ROS levels are significantly lower in BCSCs than that in NCSCs. (C, D) ROS levels are approximately 3- to 5-fold lower in BCSCs as compared with NCSCs. Data are presented as mean  $\pm$  SEM of three independent experiments. \* p < 0.05, \*\* p < 0.01 vs. CSCs.



#### Fig. 2. $H_2O_2$ treatment increases the number of ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> cells.

Flow cytometry was employed to analyze the number of ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> BCSCs at 24 h after H<sub>2</sub>O<sub>2</sub> treatment. (**A**) Representative flow cytometry graphs are presented, showing that H<sub>2</sub>O<sub>2</sub> treatment increases the number of ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> cells. (**B**) Quantification of flow cytometry data demonstrates that H<sub>2</sub>O<sub>2</sub> treatment increases the percentage of BCSCs in a dose-dependent manner. (**C**) A representative flow cytometry analysis of apoptosis in the ESA<sup>+</sup>/CD24<sup>-</sup>/CD44<sup>+</sup> subpopulations. (**D**) Flow cytometry analysis revealed that H<sub>2</sub>O<sub>2</sub> treatment has no significant effect on apoptotic cell death in BCSCs. Data are presented as mean  $\pm$  SEM of three independent experiments. \*\*\* *p*< 0.001 vs. PBS control.



#### Fig. 3. H<sub>2</sub>O<sub>2</sub> treatment impairs the mammosphere-forming potential of BCSCs.

MFA was employed to measure the mammosphere-forming capacity of BCSCs at 24 h after  $H_2O_2$  treatment. (A) Representative images of a MFA showing that  $H_2O_2$ -treated MCF-7 cells failed to produce mammospheres in culture. (B, C)  $H_2O_2$  treatment impairs the mammosphere-forming potential of BCSCs from both MCF-7 (B) and SUM159 (C) cells. (D) Representative images of a clonogenic assay showing that  $H_2O_2$  inhibits the formation of colonies in MCF-7 cells. (E, F) Decreased colony-forming capacity was observed in both MCF-7 (E) and SUM159 (F) cells following  $H_2O_2$  treatment. All data are presented as mean  $\pm$  SEM of three independent experiments. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001 vs. PBS control.

Page 14



#### Fig. 4. H<sub>2</sub>O<sub>2</sub> treatment induces premature senescence in BCSCs.

(A) Representative images of SA- $\beta$ -gal staining of senescent MCF-7 cells at 5 days after H<sub>2</sub>O<sub>2</sub> exposure. (**B**, **C**) SA- $\beta$ -gal analysis showed that H<sub>2</sub>O<sub>2</sub> induces premature senescence in both MCF-7 (**B**) and SUM159 (**C**) cells in a dose-dependent fashion. (**D**) Representative flow cytometry graphs depicting that H<sub>2</sub>O<sub>2</sub> increased SA- $\beta$ -gal activity in the ESA<sup>+</sup>/CD24<sup>-</sup>/ CD44<sup>+</sup> subpopulations of MCF-7 cells at 5 days after exposure. (**E**) Flow cytometry analysis revealed that H<sub>2</sub>O<sub>2</sub> treatment induces premature senescence in BCSCs in dose-dependent manner. (**F**) Western blot analysis indicated that H<sub>2</sub>O<sub>2</sub> treatment-induced BCSC senescence is associated with p53 activation and increased p53 and p21 expression. \*\* *p* < 0.01, \*\*\* *p* < 0.001 vs. PBS control.